We are live on ! Find out more
PBMWW

Psyence Biomedical Warrant
PBMWW

18 hedge funds and large institutions have $122K invested in Psyence Biomedical Warrant in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more capital invested

Capital invested by funds: $96.6K → $122K (+$25K)

0.91% less ownership

Funds ownership: 40.47% → 39.55% (-0.91%)

5% less funds holding

Funds holding: 19 → 18 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
18
Holders Change
-1
Holders Change %
-5.26%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
4
Closed
2
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$290

Top Sellers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
-$2.87K
2
VF
Virtu Financial
New York
-$1K
3
HCI
Harraden Circle Investments
New York
-$29
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$9
5
UBS Group
UBS Group
Switzerland
-$4
Name Holding Trade Value Shares
Change 		Change in
Stake
HCI
1
Harraden Circle Investments
New York
$27.9K -$29 -1,000 -0.1%
PAMP
2
Polar Asset Management Partners
Ontario, Canada
$16.6K – – –
MI
3
MMCAP International
Cayman Islands
$14.6K – – –
Toronto Dominion Bank
4
Toronto Dominion Bank
Ontario, Canada
$12.1K -$9 -300 -0.1%
Calamos Advisors
5
Calamos Advisors
Illinois
$10.5K – – –
SCM
6
Saba Capital Management
New York
$7.24K – – –
CS
7
Clear Street
New York
$6.25K – -7 -0%
Goldman Sachs
8
Goldman Sachs
New York
$4.86K – – –
LP
9
LMR Partners
United Kingdom
$4.86K – – –
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$3.68K – – –
TCM
11
Tenor Capital Management
New York
$3.65K – – –
WAM
12
Wolverine Asset Management
Illinois
$3.58K – – –
AC
13
Aristeia Capital
Connecticut
$2.62K -$2.87K -100,000 -46%
LPL Financial
14
LPL Financial
California
$1.19K – – –
MTCM
15
Mint Tower Capital Management
Netherlands
$1K – – –
PA
16
Parallel Advisors
California
$668 – – –
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$212 +$290 +10,119 New
AA
18
Ancora Advisors
Ohio
$121 – – –
VF
19
Virtu Financial
New York
– -$1K -27,853 Closed
UBS Group
20
UBS Group
Switzerland
– -$4 -247 Closed

PBMWW Hedge Fund Activity: Q2 2026 in Review

18 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Psyence Biomedical Warrant (PBMWW) for Q2 2026, worth a combined $122K — up 26% from $96.6K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of PBMWW and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 0 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $290. The largest seller was Aristeia Capital, cutting an estimated $2.87K.

  • 18 institutional investors held Psyence Biomedical Warrant (PBMWW) as of Q2 2026, down from 19 in Q1 2026.
  • Funds reported $122K of Psyence Biomedical Warrant stock for Q2 2026, up 26% quarter-over-quarter.
  • 1 fund opened new Psyence Biomedical Warrant positions in Q2 2026 and 2 closed out, a net change of -1 holder.
  • The largest Psyence Biomedical Warrant buyer in Q2 2026 was Susquehanna International Group, an estimated $290 added.
  • The largest Psyence Biomedical Warrant seller in Q2 2026 was Aristeia Capital, an estimated $2.87K sold.

Based on aggregated 13F filings for Q2 2026.